YUNLONG ZHANG

Dr. YUNLONG ZHANG


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2019 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
LZLei‐Xin Zou
Lei‐Xin Zou
CCChen Chen
Chen Chen
XYXiao Yan
Xiao Yan
QLQiu‐Yue Lin
Qiu‐Yue Lin
JFJiao Fang
Jiao Fang
YZYUNLONG ZHANG
YUNLONG ZHANG

24 August 2023 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Open access
XZXinxin Zhang
Xinxin Zhang
NWNing Mm Wang
Ning Mm Wang
PFPeng Mm Fu
Peng Mm Fu
YAYanliang Mm An
Yanliang Mm An
FSFangfang Msc Sun
Fangfang Msc Sun
YLYing Liu
Ying Liu
Heart failure with preserved ejection fraction (HFpEF) is highly prevalent, accounting for 50% of all heart failure patients, and is associated with significant mortality. Sodium–glucose cotransporter subtype inhibitor (SGLT2i) is recommended in the AHA and ESC guidelines for the treatment of HFpEF, but the mechanism of SGLT2i to prevent and treat cardiac remodeling and dysfunction is currently unknown, hindering the understanding of the pathophysiology of HFpEF and the development of novel therapeutics. HFpEF model was induced by a high-fat diet (60% calories from lard) + N[w]-nitro-l-arginine methyl ester (l-NAME—0.5 g/L) (2 Hit) in male Sprague Dawley rats to effectively recapture the myriad phenotype of HFpEF. This study's results showed that administration of dapagliflozin (DAPA, SGLT2 inhibitor) significantly limited the 2-Hit–induced cardiomyocyte hypertrophy, apoptosis, inflammation, oxidative stress, and fibrosis. It also improved cardiac diastolic and systolic dysfunction in a late-stage progression of HFpEF. Mechanistically, DAPA influences energy metabolism associated with fatty acid intake and mitochondrial dysfunction in HFpEF by increasing β-hydroxybutyric acid (β-OHB) levels, directing the activation of citrate synthase, reducing acetyl coenzyme A (acetyl-CoA) pools, modulating adenosine 5′-triphosphate production, and increasing the expression of mitochondrial oxidative phosphorylation system complexes I-V. In addition, following clinical DAPA therapy, the blood levels of β-OHB and citrate synthase increased and the levels of acetyl-CoA in the blood of HFpEF patients decreased. SGLT2i plays a beneficial role in the prevention and treatment of cardiac remodeling and dysfunction in HFpEF model by attenuating cardiometabolic dysregulation.

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
JBJie Bai
Jie Bai
LYLiangqingqing Yin
Liangqingqing Yin
WYWei-Jia Yu
Wei-Jia Yu
YZYUNLONG ZHANG
YUNLONG ZHANG
QLQiuyue Lin
Qiuyue Lin
HLHuihua Li
Huihua Li
Cardiac lymphatic vessel growth (lymphangiogenesis) and integrity play an essential role in maintaining tissue fluid balance. Inhibition of lymphatic lymphangiogenesis is involved in cardiac edema and cardiac remodeling after ischemic injury or pressure overload. However, whether lymphatic vessel integrity is disrupted during angiotensin II‐ (Ang II‐) induced cardiac remodeling remains to be investigated. In this study, cardiac remodeling models were established by Ang II (1000 ng/kg/min) in VEGFR‐3 knockdown (Lyve‐1Cre VEGFR‐3f/−) and wild‐type (VEGFR‐3f/f) littermates. Our results indicated that Ang II infusion not only induced cardiac lymphangiogenesis and upregulation of VEGF‐C and VEGFR‐3 expression in the time‐dependent manner but also enhanced proteasome activity, MKP5 and VE‐cadherin degradation, p38 MAPK activation, and lymphatic vessel hyperpermeability. Moreover, VEGFR‐3 knockdown significantly inhibited cardiac lymphangiogenesis in mice, resulting in exacerbation of tissue edema, hypertrophy, fibrosis superoxide production, inflammation, and heart failure (HF). Conversely, administration of epoxomicin (a selective proteasome inhibitor) markedly mitigated Ang II‐induced cardiac edema, remodeling, and dysfunction; upregulated MKP5 and VE‐cadherin expression; inactivated p38 MAPK; and reduced lymphatic vessel hyperpermeability in WT mice, indicating that inhibition of proteasome activity is required to maintain lymphatic endothelial cell (LEC) integrity. Our results show that both cardiac lymphangiogenesis and lymphatic barrier hyperpermeability are implicated in Ang II‐induced adaptive hypertrophic remodeling and dysfunction. Proteasome‐mediated hyperpermeability of LEC junctions plays a predominant role in the development of cardiac remodeling. Selective stimulation of lymphangiogenesis or inhibition of proteasome activity may be a potential therapeutic option for treating hypertension‐induced cardiac remodeling.

1 July 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
PFPeng Fu
Peng Fu
XHXiao Han
Xiao Han
QLQiuyue Lin
Qiuyue Lin
NWNing Wang
Ning Wang
FSFang‐Fang Sun
Fang‐Fang Sun
BZBo Zhang
Bo Zhang
Background: Myocardial ischemia/reperfusion (I/R) injury is a leading cause of myocardial dysfunction and is associated with inflammation, apoptosis, and fibrosis. The integrin subunit ITGAM (also known as CD11b) mainly mediates leukocyte infiltration in the inflammatory process. However, the importance of CD11b in the development of myocardial I/R injury is unclear. The goal of this study is to investigate the role of CD11b + immune cells, particularly neutrophils and macrophages, in mediating myocardial I/R injury and to evaluate the therapeutic potential of CD11b inhibition. Methods: Wild‐type mice were administered an anti‐CD11b neutralizing antibody before myocardial I/R surgery. Echocardiography and histological staining were used to evaluate cardiac function and injury, respectively. Inflammatory cells were analyzed by flow cytometry in mice and patients with myocardial infarction who underwent percutaneous coronary intervention. Activated fibroblasts from patients with myocardial infarction were detected by positron emission tomography/computed tomography with a [(18)F]‐labeled fibroblast activation protein inhibitor. Results: Our results indicated that CD11b expression and the number of CD45 + CD11b + bone marrow mononuclear cells were dramatically increased in the heart tissues of I/R‐treated mice. Moreover, compared with immunoglobulin G treatment, the pharmacological inhibition of CD11b in mice greatly alleviated cardiac dysfunction, infarct size, myocyte apoptosis, CD11b + neutrophils and macrophage infiltration, cardiac fibrosis and fibroblast activation, accompanied by the inhibition of multiple signaling pathways (Bax, caspase‐3, nuclear factor‐κB, and transforming growth factor‐β/Smad2/3) 3 days after I/R surgery. In addition, the numbers of CD15 + CD11b + neutrophils and CD14 + CD11b + monocytes and the levels of inflammatory cytokines (intercellular adhesion molecule ‐1, vascular adhesion molecule ‐1, interleukin‐1β, and interleukin‐6) as well as the levels of fibroblast activation protein inhibitor in patients with myocardial infarction were also significantly greater than those in normal controls. Conclusions: Our data demonstrate that CD11b plays an important role in promoting myocardial I/R injury through multiple signaling pathways and that targeting CD11b may represent a promising option for treating heart I/R injury.

18 August 2020 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
YZYUNLONG ZHANG
YUNLONG ZHANG
FTFei Teng
Fei Teng
XHXiao Han
Xiao Han
PLPang‐Bo Li
Pang‐Bo Li
XYXiao Yan
Xiao Yan
HLHuihua Li
Huihua Li
Atrial fibrillation (AF) is associated with inflammation and oxidative stress. Recently, we demonstrated that the chemokine‐receptor CXCR2 plays a critical role in the recruitment of monocytes/macrophages and the development of hypertension and cardiac remodelling. However, the role of CXCR2 in the pathogenesis of hypertensive AF remains unclear. AF was induced in Wistar‐Kyoto rats (WKYs) and spontaneously hypertensive rats (SHRs) administered with the CXCR2 inhibitor SB225002. Atrial remodelling, pathological changes and electrophysiology were examined. Our results showed that the chemokine CXCL1 and its receptor CXCR2 were markedly increased in atrial tissue of SHRs compared with WKYs. The administration of SB225002 to SHRs significantly reduced the elevation of blood pressure, AF inducibility and duration, atrial remodelling, recruitment of macrophages, superoxide production and conduction abnormalities compared with vehicle treatment. The administration of SB225002 to SHRs also reversed pre‐existing AF development, atrial remodelling, inflammation and oxidative stress. These effects were associated with the inhibition of multiple signalling pathways, including TGF‐β1/Smad2/3, NF‐κB‐P65, NOX1, NOX2, Kir2.1, Kv1.5 and Cx43. In conclusion, this study provides new evidence that blocking CXCR2 prevents and reverses the development of AF in SHRs, and suggests that CXCR2 may be a potential therapeutic target for hypertensive AF.

1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
YZYUNLONG ZHANG
YUNLONG ZHANG
BZBo Zhang
Bo Zhang
XHXiao Han
Xiao Han
BZBo Zhang
Bo Zhang
HLHuihua Li
Huihua Li
Myocardial ischemia/reperfusion injury (I/RI) is closely associated with energy substrate metabolism. Fibronectin 1 (Fn1) was markedly elevated in the heart of I/R pigs and ischemic patients, but its role in myocardial I/RI is controversial and the precise mechanism involved remains elusive. Herein, we tested whether blockage of Fn1 with its inhibitor (fibronectin tetrapeptide, RGDS) would alleviate myocardial I/RI. Wild‐type (WT) mice were administered with RGDS once 3 h before I/R operation and once at 24 or 48 h postreperfusion, and sacrificed at 24 or 72 h post‐I/R, respectively. Cardiac function was evaluated by echocardiography. Myocardial infarction size, apoptosis, fibrosis, and inflammation were examined via histological staining. Uptake of glucose and fatty acids were detected by positron emission tomography (PET) and computer tomography (CT) with [18F]‐2‐fluoro‐2‐deoxy‐D‐glucose (FDG) and [18F]‐fluoro‐6‐thia‐heptadecanoic acid (FTHA), respectively. Our results showed that administration of RGDS to mice remarkably limited the I/R‐induced myocardial infarct size, myocyte apoptosis, inflammation, oxidative stress, and fibrosis and improved cardiac contractile dysfunction. These protective effects were associated with upregulation of the AMP/ATP ratio and the activation of LKB1‐AMPK signaling, which subsequently increased AS160‐GLUT4‐mediated glucose and fatty acid uptake, improved mitochondrial dynamic imbalance, and inactivated TGF‐β and NF‐κB signals in the I/R heart. In conclusion, the current study identified that blocking Fn1 protects against myocardial I/RI likely through activating the LKB1‐AMPK‐dependent signals and highlights that inhibition of Fn1 may be a novel therapeutic option for treating ischemic heart diseases.